Knight Therapeutics | GUD - Cost Of Sales


Knight Therapeutics reported CAD82.22M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Akebia Therapeutics USD 10.34M 441K Dec/2025
Alaunos Therapeutics USD 0 18K Sep/2024
Aurora Cannabis CAD 8.22M 80.38M Mar/2026
Avita Medical AUD 3.3M 166K Dec/2025
Canopy Growth CAD 62.98M 9.91M Mar/2026
Cronos Group USD 26.48M 2.26M Mar/2026
Ionis Pharmaceuticals USD 3M 5M Mar/2026
IQVIA Holdings USD 3.08B 161M Mar/2026
Knight Therapeutics CAD 82.22M 1.03M Dec/2025
Moderna USD 955M 503M Mar/2026
Omeros USD 33.16M 18.52M Jun/2024
Organigram Holdings CAD 43.39M 13.54M Mar/2026
Organon & Co USD 677M 89M Mar/2026
Revvity USD 323.46M 26.93M Mar/2026
Tilray USD 164.37M 8.41M Sep/2025
Viatris USD 2.36B 195.9M Mar/2026
Xeris Pharmaceuticals USD 10.57M 3.08M Mar/2026